Format

Send to

Choose Destination
J Biomed Sci. 2019 Oct 28;26(1):87. doi: 10.1186/s12929-019-0578-x.

Human iPSC banking: barriers and opportunities.

Author information

1
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
2
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. phsieh@ibms.sinica.edu.tw.
3
Graduate Institute of Medical Genomics and Proteomics and Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. phsieh@ibms.sinica.edu.tw.
4
Cardiovascular Surgery Division, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan. phsieh@ibms.sinica.edu.tw.

Abstract

The introduction of induced pluripotent stem cells (iPSCs) has opened up the potential for personalized cell therapies and ushered in new opportunities for regenerative medicine, disease modeling, iPSC-based drug discovery and toxicity assessment. Over the past 10 years, several initiatives have been established that aim to collect and generate a large amount of human iPSCs for scientific research purposes. In this review, we compare the construction and operation strategy of some iPSC banks as well as their ongoing development. We also introduce the technical challenges and offer future perspectives pertaining to the establishment and management of iPSC banks.

KEYWORDS:

Cell bank; Induced pluripotent stem cell (iPSC); Personalized medicine

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center